Jeffrey Lieberman

Jeffrey Alan Lieberman (born 1948) is an American psychiatrist who specializes in schizophrenia and related psychoses and their associated neuroscience (biology) and drugs. He was principal investigator for CATIE, the largest and longest independent study ever funded by the United States National Institute of Mental Health to examine existing therapies for schizophrenia.[2]

Jeffrey A. Lieberman
Born1948
CitizenshipAmerican
Alma materMiami University (B.S.)
George Washington University Medical School (M.D.)
Saint Vincent's Catholic Medical Center
Known forSchizophrenia research, NIMH CATIE study[1]
Children2
AwardsLieber Prize for Schizophrenia Research from the National Association for Research in Schizophrenia and Affective Disorders; the Adolph Meyer Award from the American Psychiatric Association; the Research Award from the National Alliance on Mental Illness, and the Neuroscience Award from the International College of Neuropsychopharmacology
Scientific career
FieldsPsychiatry
InstitutionsAmerican Psychiatric Association, Columbia University Vagelos College of Physicians and Surgeons, New York State Psychiatric Institute, University of North Carolina School of Medicine, Mount Sinai School of Medicine, Albert Einstein College of Medicine, Zucker Hillside Hospital of Long Island Jewish Medical Center

He was previously president of the American Psychiatric Association from May 2013 to May 2014.[3]

Lieberman is the Lawrence E. Kolb Professor and Chairman of Psychiatry at the Columbia University Vagelos College of Physicians and Surgeons and director of the New York State Psychiatric Institute. He also holds the Lieber Chair and directs the Lieber Center for Schizophrenia Research in the Department of Psychiatry at Columbia and serves as the psychiatrist in chief of NewYork-Presbyterian Hospital/Columbia University Irving Medical Center.[4]

Education and early career

Lieberman graduated from Miami University in 1970, and then received his medical degree from the George Washington School of Medicine in 1975. Following his postgraduate training in psychiatry at St. Vincent's Hospital and Medical Center of New York Medical College, he was on the faculties of the Mount Sinai School of Medicine and Albert Einstein College of Medicine, and served as director of research at the Zucker Hillside Hospital of Long Island Jewish Medical Center.[4]

Prior to moving to Columbia University, he was vice chairman for Research and Scientific Affairs in the UNC Department of Psychiatry and Director of the Mental Health and Neuroscience Clinical Research Center at the University of North Carolina at Chapel Hill School of Medicine.[4]

Research

Lieberman's research has focused on the neurobiology, pharmacology and treatment of schizophrenia and related psychotic disorders. In this context, his work has advanced our understanding of the natural history and pathophysiology of schizophrenia and the pharmacology and clinical effectiveness of antipsychotic drugs.[4]

His research has been supported by grants from the National Institutes of Health and the NARSAD, Stanley, and Mental Illness Foundations.[4]

Lieberman's work has extended beyond biomedical research and clinical psychiatry into public policy and advocacy for enhancing awareness of mental illness and improving mental health care, as well as diminishing stigma. In this context, Dr. Lieberman actively contributed to government policy and legislation including the Mental Health Parity and Addiction Equity Act, The Patient Protection and Affordable Care Act and the Helping Families in Mental Health Crisis Act, and has been a frequent public spokesperson in the media on mental illness and psychiatry.

CATIE study

Lieberman served as principal investigator for Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) sponsored by the National Institute of Mental Health (NIMH).[1] The investigators compared a, "first-generation antipsychotic, perphenazine, with several newer drugs in a double-blind study".[5] "Probably the biggest surprise of all was that the older medication produced about as good an effect as the newer medications, three of them anyway, and did not produce neurological side effects at greater rates than any of the other drugs," Lieberman told The New York Times.[6]

Publications

Lieberman's work has been reported in more than 700 articles in the scientific literature and he has edited or co-edited 17 books, including the textbook Psychiatry, currently in its second edition, Textbook of Schizophrenia, Comprehensive Care of Schizophrenia, Psychiatric Drugs and Ethics in Psychiatric Research: A Resource Manual on Human Subjects Protection.[4]

He also serves, or has served, as associate editor of the American Journal of Psychiatry, Biological Psychiatry, Neuropsychopharmacology, Acta Psychiatrica Scandinavica, Schizophrenia Research, NeuroImage, The International Journal of Neuropsychopharmacology, and Schizophrenia Bulletin.

In 2015 he published the critically acclaimed book Shrinks: the Untold Story of Psychiatry (Little Brown) for general audienceshttps://www.nytimes.com/2015/03/29/books/review/shrinks-by-jeffrey-a-lieberman-with-ogi-ogas.html, and delivered a TED Talk on Stigma and Mental Illness. <https://www.nytimes.com/2015/03/29/books/review/shrinks-by-jeffrey-a-lieberman-with-ogi-ogas.html></ref>A four-part series, tentatively titled In Search of Madness: The Untold Story of Mental Illness, based on his book, Shrinks, is currently in production and scheduled for prime-time national broadcast on PBS in April 2022.

His new book, A Once Malignant Malady: How schizophrenia went from a sentence of madness to a preventable illness will be published by Scribner’s of Simon and Shuster in April of 2022.

Awards, honors, and memberships

Lieberman is a member of the National Academy of Sciences Institute of Medicine and a fellow of the American Association for the Advancement of Science (AAAS). He received the Lieber Prize for Schizophrenia Research from NARSAD,[7] the Adolph Meyer Award from the American Psychiatric Association (APA), the Stanley R. Dean Award for Schizophrenia Research from the American College of Psychiatrists, the APA Research Award, the APA Kempf Award for Research in Psychobiology, the APA Gralnick Award for Schizophrenia Research, the Ziskind-Somerfeld Award of the Society of Biological Psychiatry, the Ernest Strecker Award of the University of Pennsylvania, the Lilly Neuroscience Award from the Collegium Internationale Neuro-Psychopharmacologicum for Clinical Research, the Scientific Research Award[8] and the Exemplary Psychiatrist Award from the National Alliance on Mental Illness, the Ed Hornick Memorial Award of The New York Academy of Medicine,[9] the Strecker Award of the Department of Psychiatry at the University of Pennsylvania.[10]

He is or has been a member of the advisory committee for Neuropharmacologic and Psychopharmacologic Drugs of the Food and Drug Administration, the Planning Board for the Surgeon General's Report on Mental Health, the Committee on Research on Psychiatric Treatments of the APA, the APA Work Group for the Development of Schizophrenia Treatment Guidelines, the Brain Disorders and Clinical Neuroscience Review Committee, the National Advisory Mental Health Council of the NIMH, and currently chairs the APA Council of Research.

Controversy

Conflict of Interest

Lieberman's work necessitates[According to who?] close work with many leading pharmaceutical companies, and raises questions of improper conduct due to extrajudicial funding. Lieberman has consistently filed disclosure of his funding and has not been accused of any undisclosed improprieties. Lieberman neither accepts nor receives any personal financial remuneration for consulting, speaking or research activities from any pharmaceutical, biotechnology or medical device companies. He receives support administered through Columbia University and the Research Foundation for Mental Hygiene in the form of funding and medication supplies for investigator initiated research

On multiple occasions, Lieberman has publicly disclosed information about potential conflicts of interest. Lieberman's most recent conflict of interest disclosure came in 2018 Lieberman JA, First MB. Psychotic Disorders. N Engl J Med. 2018 Jul 19;379(3):270-280. doi: 10.1056/NEJMra1801490 Review and in 2019 Lieberman JA, Small SA, Girgis RR. Early Detection and Preventive Intervention in Schizophrenia: From Fantasy to Reality. Am J Psychiatry. 2019 Oct 1;176(10):794-810. doi: 10.1176/appi.ajp.2019.19080865

Criticism

Lieberman has received criticism from an ex-patient for his demeanor and his close ties to the pharmaceutical industry.[11][12] Bruce E. Levine critiqued on the website Mad in America that Lieberman removed anti-psychotic drugs from patients and administered psychotogenic drugs in experiments, which could be considered a breaking of the Declaration of Geneva , specifically "THE HEALTH AND WELL-BEING OF MY PATIENT will be my first consideration". The medical procedures could also be breaking of the Nuremberg Code of ethics , specifically "The voluntary consent of the human subject is absolutely essential."[13][14][15][16][17][18]

Personal life

He resides in New York City[4] with his wife, Rosemarie,[19] and two sons.[20]

Notes
  1. "Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE)". National Institute of Mental Health. 2005 to 2008. Archived from the original on May 26, 2013. Retrieved May 26, 2013. Check date values in: |date= (help)
  2. "Questions and Answers About the NIMH Clinical Antipsychotic Trials of Intervention Effectiveness Study (CATIE) — Phase 1 Results". National Institute of Mental Health, U.S. Department of Health and Human Services. September 2005. Archived from the original on May 26, 2013. Retrieved May 28, 2013.
  3. "Jeffrey A. Lieberman". Columbia University. Retrieved May 26, 2013.
  4. "Jeffrey Lieberman, M.D." Columbia University Department of Psychiatry. 2005 to 2008. Retrieved May 26, 2013. Check date values in: |date= (help)
  5. Lieberman, Jeffrey A.; et al. (September 22, 2005). "Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia". The New England Journal of Medicine. Massachusetts Medical Society. 353 (12): 1209–1223. doi:10.1056/NEJMoa051688. PMID 16172203.
  6. Carey, Benedict (September 20, 2005). "Little Difference Found in Schizophrenia Drugs". The New York Times. Retrieved May 30, 2013.
  7. "Prestigious Lieber Prize for Research Awarded to Jeffrey A. Lieberman, M.D". National Institute of Mental Health. October 12, 2006. Archived from the original on April 27, 2013. Retrieved May 26, 2013.
  8. "Reception and Presentation of the 2011 NAMI Scientific Research Award". National Alliance on Mental Illness. Archived from the original on October 3, 2013. Retrieved May 26, 2013.
  9. "Jeffrey A. Lieberman Receives Hornick Award; Delivers Lecture on Early Interventions for Schizophrenia". The New York Academy of Medicine. January 12, 2012. Retrieved May 26, 2013.
  10. "Previous Strecker Award Recipients". The Trustees of the University of Pennsylvania. Retrieved May 26, 2013.
  11. Stone, Judy (May 24, 2013). "Anti-Psychiatry Prejudice? A response to Dr. Lieberman". Scientific American. Retrieved May 30, 2013.
  12. "CAFE Comparison of Atypicals in First Episode of Psychosis: ClinicalTrials.gov Identifier NCT00034892 (completed)". U.S.National Institutes of Health. May 2, 2002 to March 2005. Retrieved May 30, 2013. Check date values in: |date= (help)
  13. Lieberman JA, Kane JM, Gadaleta D, Brenner R, Lesser MS, Kinon B (1984). "Methylphenidate challenge as a predictor of relapse in schizophrenia". Am J Psychiatry. 141 (5): 633–8. doi:10.1176/ajp.141.5.633. PMID 6143506.CS1 maint: multiple names: authors list (link)
  14. Lieberman JA, Kane JM, Sarantakos S, Gadaleta D, Woerner M, Alvir J, Ramos-Lorenzi J (1987). "Prediction of relapse in schizophrenia". Arch Gen Psychiatry. 44 (7): 597–603. doi:10.1001/archpsyc.1987.01800190013002. PMID 2886110.CS1 maint: multiple names: authors list (link)
  15. Jody D, Lieberman JA, Geisler S, Szymanski S, Alvir JM (1990). "Behavioral response to methylphenidate and treatment outcome in first episode schizophrenia". Psychopharmacol Bull. 26 (2): 224–30. PMID 2236460.CS1 maint: multiple names: authors list (link)
  16. Robinson D, Mayerhoff D, Alvir J, Cooper T, Lieberman J (1991). "Mood responses of remitted schizophrenics to methylphenidate infusion". Psychopharmacology (Berl). 105 (2): 247–52. doi:10.1007/bf02244317. PMID 1796130. S2CID 21625597.CS1 maint: multiple names: authors list (link)
  17. Lieberman JA, Alvir J, Geisler S, Ramos-Lorenzi J, Woerner M, Novacenko H, Cooper T, Kane JM (1994). "Methylphenidate response, psychopathology and tardive dyskinesia as predictors of relapse in schizophrenia". Neuropsychopharmacology. 11 (2): 107–18. doi:10.1038/npp.1994.40. PMID 7840862.CS1 maint: multiple names: authors list (link)
  18. Koreen AR, Lieberman JA, Alvir J, Chakos M (1997). "The behavioral effect of m-chlorophenylpiperazine (mCPP) and methylphenidate in first-episode schizophrenia and normal controls". Neuropsychopharmacology. 16 (1): 61–8. doi:10.1016/S0893-133X(96)00160-1. PMID 8981389.CS1 maint: multiple names: authors list (link)
  19. "Rainbow Light Home". Blessed Herbs. Archived from the original on 2016-12-21. Retrieved 2016-12-14.
  20. "Jeffrey Lieberman, M.D." clintara.com. Archived from the original on 2016-06-24. Retrieved 2016-12-14.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.